

ASX ANNOUNCEMENT

4 March 2026

Little Green Pharma Ltd (ASX: LGP)

RESULTS OF FIRST COURT HEARING



For personal use only

Little Green Pharma Ltd (ASX:LGP) (**LGP** or the **Company**) refers to its announcement dated 14 January 2026 in relation to the Company's proposed acquisition of 100% of the issued capital of Cannatrek Ltd (**Cannatrek**) by way of scheme of arrangement under Part 5.1 of the *Corporations Act 2001* (Cth) (**Corporations Act**) (**Scheme**).

Capitalised terms used in this announcement have the meaning given to them in the scheme implementation deed, unless otherwise specified.

COURT ORDERS

LGP is pleased to announce that the Supreme Court of Victoria (**Court**) has today made orders for the convening of a meeting of Cannatrek Shareholders (**Scheme Meeting**) and approving the dispatch of an explanatory statement to Cannatrek Shareholders providing information about the Scheme, together with the notice of Scheme Meeting (**Scheme Booklet**).

SCHEME MEETING

The Scheme Meeting will take place in person and online on 10 April 2026 at 9.30am (Melbourne time), at the offices of K&L Gates, 25/525s Collins Street, Melbourne VIC 3000 and accessible online at <https://meetings.lumiconnect.com/300-701-212-756>. All Cannatrek Shareholders who are registered as a Cannatrek Shareholder at 7.00pm (Melbourne time) on 8 April 2026 will be entitled to vote at the Scheme Meeting.

Cannatrek Shareholders who are unable, or do not wish, to attend the Scheme Meeting are encouraged to submit a directed proxy as early as possible, and, in any event, no later than 48 hours before the Scheme Meeting.

Further information on how Cannatrek Shareholders can participate and vote at the Scheme Meeting, or lodge a proxy form, will be provided in the Notice of Scheme Meeting, included in the Scheme Booklet.

SCHEME BOOKLET

The Scheme Booklet is expected to be registered with the Australian Securities and Investments Commission (**ASIC**) on 4 March 2026. The Scheme Booklet (including the Independent Expert's Report) will then be released to LGP's ASX market announcements platform at <https://www.asx.com.au/> following registration with ASIC. A copy of the Scheme Booklet will also be available for viewing and download at the Company's website at <https://investlittlegreenpharma.com/> following release on ASX.

Cannatrek Shareholders should carefully read the Scheme Booklet in its entirety before making any decision in relation to the Scheme. Cannatrek Shareholders are encouraged to seek independent legal, financial, tax or other professional advice before deciding how to vote in respect of the Scheme Meeting.

LGP SHAREHOLDER MEETING

Following registration of the Scheme Booklet with ASIC, LGP will dispatch a notice of meeting and explanatory memorandum to LGP Shareholders (**LGP Notice of Meeting**) in respect of the LGP Resolutions required to be approved by LGP Shareholders as a condition of the Scheme.

The LGP Shareholder meeting will be held via Zoom webinar currently scheduled for 10 April 2026 at 3.00pm (Perth time). Details on how to register for and remotely attend the LGP Shareholder Meeting will be released to LGP's ASX market announcements platform at <https://www.asx.com.au/> and on the Company's website at <https://investlittlegreenpharma.com/site/investor-centre/extraordinary-general-meetings>.

All LGP Shareholders who are registered as a LGP Shareholder at 3.00pm (Perth time) on 8 April 2026 will be entitled to vote at the LGP Shareholder Meeting.

LGP Shareholders who are unable, or do not wish, to attend the LGP Shareholder Meeting are encouraged to submit a directed proxy as early as possible, and, in any event, no later than 48 hours before the LGP Shareholder Meeting.

Further information on how to participate and vote at the LGP Shareholder Meeting will be provided in the LGP Notice of Meeting. Any updates regarding the LGP Shareholder Meeting will be provided following ASX confirmation of the draft LGP Notice of Meeting.

BOARD RECOMMENDATIONS AND VOTING INTENTIONS

The Cannatrek Board has unanimously recommended that Cannatrek Shareholders vote in favour of the Scheme, in the absence of a Superior Proposal and subject to the Independent Expert concluding (and continuing to conclude) that the Scheme is in the best interests of Cannatrek shareholders. Subject to those same qualifications, each Cannatrek Director intends to vote (or procure the voting of) all Cannatrek Shares held or controlled by them at the time of the Scheme Meeting in favour of the Scheme.

The LGP Board unanimously recommends that LGP Shareholders vote in favour of the LGP Resolutions that will be contained in the LGP Notice of Meeting, in the absence of an LGP Superior Proposal. Each LGP Director will, in the absence of a LGP Superior Proposal, vote (or procure the voting of) all LGP Shares held or controlled by them at the time of the LGP Shareholder Meeting in favour of the LGP Resolutions.

For personal use only

INDICATIVE TIMETABLE

The key dates and times for the Scheme are as follows:

Event	Date
First Court Date for convening the Scheme Meeting	2:15pm (Melbourne time) on 3 March 2026
Date of the Scheme Booklet	4 March 2026
Latest time and date for receipt of proxy forms and powers of attorney from Cannatrek Shareholders for the Scheme Meeting	9.30am (Melbourne time) on 8 April 2026
Time and date for determining eligibility of Cannatrek Shareholders to vote at the Scheme Meeting	7.00pm (Melbourne time) on 8 April 2026
Latest time and date for receipt of proxy forms and powers of attorney from LGP Shareholders for the LGP Shareholder Meeting	3.00pm (Perth time) on 8 April 2026
Time and date for determining eligibility of LGP Shareholders to vote at the LGP Shareholder Meeting	3.00pm (Perth time) on 8 April 2026
Scheme Meeting	9.30am (Melbourne time) on 10 April 2026
LGP Shareholder Meeting	3.00pm (Perth time) on 10 April 2026
If the Scheme is approved by the Requisite Majorities of Cannatrek Shareholders	
Second Court Date for approval of the Scheme	9:30am (Melbourne time) on 21 April 2026
Effective Date Court order lodged with ASIC and announcement to the ASX by LGP	22 April 2026
Scheme Record Date for determining entitlements to Consideration Securities	7.00pm (Melbourne time) on 24 April 2026
Implementation Date and provision of Consideration Securities	1 May 2026

Notes:

- All dates following the date of the Scheme Meeting are indicative only and, among other things, are subject to all necessary approvals from the Court. Any changes to the above timetable (which may include an earlier or later date for the Second Court Hearing) will be announced through the ASX (by LGP) and notified via Boardroom, Cannatrek's Share Registry. Cannatrek may vary the timetable detailed above subject to the approval of such variation by LGP, the Court and ASIC where required.

For personal use only

This announcement is authorised for release by the Board of LGP

For further information please contact:

Alistair Warren
Company Secretary

Little Green Pharma
 E: cosec@lgp.global
 T: +61 8 6280 0050

Paul Long
Managing Director

Little Green Pharma
 E: p.long@lgp.global
 T: +61 8 6280 0050



About Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) is a leading global medicinal cannabis company with vertically integrated operations across Europe and Australia.

LGP has a diverse and growing portfolio of cannabis-based medicines, distributed across Australia and over 12 export markets via a network of wholesalers, pharmacies, clinics, and GPs. The Company generates revenue through both the sale of medicinal cannabis products and its domestic Health House distribution business, which allows it to capture value across the supply chain and to adapt to evolving regulatory environments while building defensible commercial positions in high-growth markets.

Operating three production facilities in Denmark and Australia – including the largest facility in Europe – LGP is the one of the top three suppliers in Australia, the largest supplier into France, and a significant supplier into Germany and the UK, positioning it as a key player in global medicinal cannabis markets.

With diversified revenue streams, a presence in over a dozen export markets, and a high net tangible asset position relative to its enterprise value, LGP offers investors leveraged exposure to global medicinal cannabis demand and a clear platform for scalable growth.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email to help reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

For personal use only